Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

7 Jan 2021

CytoDel successfully delivers neuronal antibody in animal models of botulism

CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the Company's lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, "Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism," can be found here.

7 Jan 2021

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Researchers who studied antibody and immune cell responses in more than 180 men and women who had recovered from COVID-19 report these patients' immune memory to the virus - across all immune cell types studied - was measurable for up to 8 months after symptoms appeared.

7 Jan 2021

Non-toxic versions of botulism toxins can deliver therapeutic antibodies to treat botulism

Taking advantage of the chemical properties of botulism toxins, two teams of researchers have fashioned non-toxic versions of these compounds that can deliver therapeutic antibodies to treat botulism, a potentially fatal disease with few approved treatments.

6 Jan 2021

In-silico modeling provides new understanding of immune response to SARS-CoV-2

The COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has crippled global healthcare systems and triggered an economic crisis in many countries. The pandemic is not showing signs of a slowdown even in 2021 with a new and more infectious variant of the virus wreaking havoc in the UK and many other parts of the world.

6 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

In a recent bioRxiv* preprint paper, US researchers mapped in detail how mutations to the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affected antibody binding in convalescent human serum – and revealed that it is influenced by mutations at only a handful of dominant epitopes.

6 Jan 2021

Researchers identify the missing link between intestinal disease and brain injury in premature infants

Physicians have long known that necrotizing enterocolitis (NEC), a potentially lethal inflammatory condition that destroys a premature infant's intestinal lining, is often connected to the development of severe brain injury in those infants who survive.

6 Jan 2021

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

A large clinical trial, known as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2), is set to take place, which aims to test monoclonal antibody efficacy and safety in people who have mild or moderate COVID-19.

6 Jan 2021

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

A new study shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.

6 Jan 2021

Are SARS-CoV-2 antibodies associated with disease enhancement?

As SARS-CoV-2 continues to wreak its havoc, antibodies that neutralize the virus and protect against infection have become an important focus of research. However, there is a concern as to whether these antibodies can actually enhance the disease.

6 Jan 2021

A paper-based sensor for detecting COVID-19

News-Medical talks to Dipanjan Pan about the development of a paper-based electrochemical sensor that can detect COVID-19 in less than five minutes.

5 Jan 2021

Researchers develop immunity monitoring to determine the efficacy of COVID-19 vaccine

As the COVID-19 vaccine becomes available to the public, immunity monitoring will play an important role in determining whether the vaccine is effective for an individual, and for how long.

5 Jan 2021

New, rapid antibody test gives detailed information on how the immune system reacts to Covid-19

A new type of antibody test is being developed by researchers at Linnaeus University and the bioanalysis company Attana. Compared to the binary antibody tests used today, this rapid test can give more detailed information on how our immune systems react to Covid-19 and other types of viruses and bacteria.

29 Dec 2020

Severity of COVID-19 correlates with the ratio of antibodies targeting crucial viral protein

COVID-19 antibodies preferentially target a different part of the virus in mild cases of COVID-19 than they do in severe cases, and wane significantly within several months of infection, according to a new study by researchers at Stanford Medicine.

24 Dec 2020

SARS-CoV-2 spike-antibody binding strength and hydrogen bond numbers are temperature dependent, study finds

A new preprint on the bioRxiv* server describes the interactions between the binding spike protein of the SARS-CoV-2 virus with the antibodies. Earlier studies have addressed the similarity in the 3D structures of the spike protein in the two SARS viruses as seen on cryo-EM.

24 Dec 2020

Anti-SARS-CoV-2 NTD-directed antibodies are protective against lethal infection

As the world struggles to contain the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for over 1.6 million deaths and 76 million infections globally, researchers are trying to pin down the determinants of lethality, of infectivity and of protection. Such data would help contain its spread and develop preventive and therapeutic antivirals and vaccines. A new preprint that appeared recently on the bioRxiv* server describes the high degree of protection afforded by antibodies that target the N-terminal domain (NTD) of the virus.

24 Dec 2020

Higher BMI linked to increased risk of SARS-CoV-2 infection

Researchers at the University of Miami Miller School of Medicine, USA, revealed that the spike-specific immunoglobulin G antibodies in obese people are negatively associated with body mass index (BMI) and serum levels of proinflammatory and metabolic markers of pulmonary inflammation.

24 Dec 2020

Kobe University and Sysmex conduct joint research on ELISPOT method for identifying COVID-19

Kobe University and Sysmex Corporation have been engaged in joint research on the ELISPOT method, a new blood test for identifying the novel coronavirus disease (COVID-19).

24 Dec 2020

SARS-CoV-2 infection increases risk of severe COVID-19 in pregnant women, newborns

Recent analyses indicate that pregnant women and newborns may face elevated risks of developing more severe cases of COVID-19 following SARS-CoV-2 infection.

24 Dec 2020

Antibody News and Research

Further Reading

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

CytoDel successfully delivers neuronal antibody in animal models of botulism

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Non-toxic versions of botulism toxins can deliver therapeutic antibodies to treat botulism

In-silico modeling provides new understanding of immune response to SARS-CoV-2

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

Researchers identify the missing link between intestinal disease and brain injury in premature infants

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

Are SARS-CoV-2 antibodies associated with disease enhancement?

A paper-based sensor for detecting COVID-19

Researchers develop immunity monitoring to determine the efficacy of COVID-19 vaccine

New, rapid antibody test gives detailed information on how the immune system reacts to Covid-19

Severity of COVID-19 correlates with the ratio of antibodies targeting crucial viral protein

SARS-CoV-2 spike-antibody binding strength and hydrogen bond numbers are temperature dependent, study finds

Anti-SARS-CoV-2 NTD-directed antibodies are protective against lethal infection

Higher BMI linked to increased risk of SARS-CoV-2 infection

Kobe University and Sysmex conduct joint research on ELISPOT method for identifying COVID-19

SARS-CoV-2 infection increases risk of severe COVID-19 in pregnant women, newborns

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo